The FDA’s newly formed Office of Pharmaceutical Quality (OPQ) will update its GMP inspections process to add risk-based factors to give sites with higher risk more attention and reward sites that exceed basic compliance.
This New Inspection Protocol Project (NIPP) changes GMP inspections by standardizing data gathering during inspections, using a question-answer based reports with a semi-quantitative scoring to allow for comparisons within and between sites, and a common inspection report structure.
The NIPP program is expected to start in 2017 as a pilot program to collect feedback and experience from the inspectors before it is formally implemented. As FDA inspections become more transparent and semi-quantitative, it is bound to be mutually beneficial to both FDA and the industry. The program was one of the 5 areas of priority for OPQ.
ABSTRACT (from the document): An analytical procedure must be demonstrated to be fit for its intended purpose. It is useful to consider the entire lifecycle of an analytical procedure, i.e., its design and development, qualification, and continued verification. The current concepts of validation, verification, and transfer of procedures address portions of the lifecycle but do not consider it holistically. The purpose of this proposed new chapter is to more fully address the entire procedure lifecycle and define concepts that may be useful. This approach is consistent with the concept of quality by design (QbD) as described in International Council for Harmonisation (ICH) Q8-R2, Q9, Q10, and Q11. The lifecycle approach can potentially be applied to all procedures, although the level of effort should be consistent with the complexity and criticality of the procedure.
Quality agreements are critical to ensure you and your contract manufacturer define each other’s roles and responsibilities with respect to quality. On November 22, 2016, the FDA released the finalized guidelines that specify what should go into quality agreements between pharmaceutical companies and outsourced contract manufacturers.
This guidance applies to commercial manufacturing for human drugs, veterinary drugs, certain combination products, biological and biotechnology products, finished products, APIs, drug substances, in-process materials, and drug constituents of combination drug/device products.
It does not apply to Type A medicated articles and medicated feed, medical devices, dietary supplements, or human cells, tissues, or cellular or tissue-based products regulated solely under section 361 of the Public Health Service Act and 21 CFR part 1271.
Quality metrics are used throughout our industry to drive continuous improvement efforts in manufacturing. Collecting the right quality metrics is critical to ensure compliance. Quality metrics can also help the FDA in developing compliance and inspection policies and procedures by allowing the FDA to:
Use a risk-based inspection scheduling of drug manufacturers
Improve ability to predict and possibly mitigate future drug shortages
Encourage the pharmaceutical industry to implement state-of-the-art, innovative quality management systems for manufacturing.
The revised draft guidance includes an explanation of how the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) intend to utilize submitted data and quality metrics to help ensure that their policies and practices continue to support continuous improvement and innovation.
FDA is initiating a voluntary reporting phase of the FDA quality metrics reporting program where they expect to learn more about a limited set of quality metrics, associated analytics, and improve the FDA quality metrics reporting program.
During the voluntary phase of the reporting program, FDA will accept voluntary submissions of data from drug manufacturing firms involved in the manufacture, preparation, propagation, compounding, or processing of finished dosage forms (FDF) or active pharmaceutical ingredients (API) used in the manufacture of “covered drug products.”
For more information and to download the guidance, click here.
Does your company handle investigational drug products (IDP) the same as your commercial products? If so, you may want to consider the proposed new USP chapter on storage and transport of IDP as an addition to the Good Storage and Distribution Practices for Drug Products chapters . This new subchapter should focus on investigational drug products (IDPs; investigational medicinal products in Europe, IMPs). Transport of small quantities of product to multiple sites, minimal stability data, temperature excursions of single containers along with different distribution requirements in various countries make this a challenge for most companies. To address these challenges, the new chapter proposes the following requirements:
Storage in a safe and secured area at labelled storage conditions
Segregation for IDPs not dispensed yet and for IDPs awaiting return to sponsor or contractor
Site qualification audits need to be performed
Anticipation and tracking of expiry or re-test extensions (according to different local regulatory requirements)
Packaging qualifications should be the same as for commercially available drug products
Consideration of important distribution risk factors (e.g. distance, time, temperature, handoffs, packaging)
Confirmation that proper steps are taken to ensure IDP supply chain integrity (including checklists for patients)
Unblinded IDPs should be quarantined
Comparators should be shipped and stored according their (new) IDP labeling
This new chapter also gives a detailed example for calculating a rating of shipment risk to help identify probability and impact of errors in the supply chain.
FDA will now require that certain regulatory submissions conform to the electronic Common Technical Document (eCTD) format. In addition, study data will have to be submitted in standardized format for certain studies. The eCTD has been the standard format for submitting applications, amendments, supplements, and reports to the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) since 2008 and makes it easier for FDA to review data, approve new drugs, and monitor drugs after they go on the market. It also simplifies the process for submitters, because the CTD format is used by drug regulatory agencies in many countries.
Starting on May 5, 2017, eCTD will be required for applications submitted to CDER and CBER for the following:
New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), and all subsequent submissions to these types of applications, including amendments, supplements, and reports, even if the original submission was filed before the requirements went into effect.
Master files, such as Drug Master Files (DMFs), which are considered to be submissions to an IND, NDA, ANDA, or BLA.
Combination products (if CDER or CBER is designated as the lead center).
For a complete listing of all documents and supportive files needed in order to submitelectronically, refer to the eCTD Web page at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/
Does your medical device come into direct or indirect contact with the human body? If so, the FDA has released a guidance document on the Use of International Standard ISO 10993-1. This guidance will help you determine the potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body. The scope is limited to the biological evaluation of sterile and non-sterile medical devices that come into direct or indirect contact with the human body. It specifically covers the use of ISO 10993-1 but also is relevant to other biocompatibility standards (e.g., other parts of the ISO 10993 series of standards, ASTM, ICH, OECD, USP). Topics covered in this guidance are:
Use of risk assessments for biocompatibility evaluations for a proposed medical device
Use of ISO 10993-1 and the FDA-modified matrix to determine the relevant biocompatibility endpoints for an evaluation
General biocompatibility testing considerations, including test article preparation;
Specific considerations for the following testing: cytotoxicity, sensitization, hemocompatibility, pyrogenicity, implantation, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and degradation assessments
Chemical assessment recommendations
Considerations for labeling devices as “-free.”
It also contains valuable resources in the appendices such as: Device Master Files for Biocompatibility Evaluations, Summary Biocompatibility Documentation, Biocompatibility Evaluation Flow Chart, Content of a Biocompatibility Test Report and Component and Device Documentation Examples.
Are you up to date on process validation requirements for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submissions for the EU? Process validation is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an active substance or intermediate meeting its predetermined specifications and quality attributes (ICH Q7).
The EMA just published a new guideline that addresses the data requirements for process characterization and verification for submission of a marketing authorization application or variation.
These principles apply to recombinant proteins and recombinant polypeptides, their derivatives, and products of which they are components (e.g. conjugates). This guideline discusses process characterization and process verification requirements. It also includes points to consider such as evaluation and verification of the upstream and downstream processes, issues related to single use equipment and multiple harvests, reprocessing, hold time, storage, transportation, and multi-facility production.
How do you handle post-approval changes to your products? New draft FDA guidance document establishes a framework to ensure you effectively use your product and process knowledge and understanding to prepare a Comparability Protocol that employs the tools in ICH Q8 to Q11. It also provides guidance on a robust control strategy, incorporates risk management over the product’s life cycle and describes elements of an effective pharmaceutical quality system.